Euroapi S.A. EAPIF
0.89 USD 0.00 (+0.00%)
At closeNov 10, 2026, 4:00 PM EST
1.71 Day range 1.71
0.8446 52-week range 3.59
- YTD
- -66.19%
- 1 year
- -75.23%
News
businesswire.com Medisca and EUROAPI Form Strategic Partnership to Strengthen API Access for Pharmaceutical Compounding MONTREAL--(BUSINESS WIRE)-- #APIs--Medisca and EUROAPI have formed a strategic partnership focused on expanding API access for pharmaceutical compounding, creating differentiated access in North…
seekingalpha.com Euroapi S.A. (EAPIF) Q2 2026 Earnings Call Transcript Euroapi S.A. (EAPIF) Q2 2026 Earnings Call Transcript
globenewswire.com EUROAPI statement regarding the Brindisi site Press Release Paris – May 13, 2026 – EUROAPI takes note of local media reports regarding its Brindisi site. As previously communicated, the review of strategic options for certain industrial assets…
globenewswire.com EUROAPI - Availability of the 2025 Universal Registration Document Press Release Availability of the 2025 Universal Registration Document, including the Annual Financial Report Paris – March 27, 2026 – EUROAPI announces the publication of its 2025 Universal…
seekingalpha.com Euroapi S.A. (EAPIF) Q4 2025 Earnings Call Transcript Euroapi S.A. (EAPIF) Q4 2025 Earnings Call Transcript
defenseworld.net Euroapi S.A. (OTCMKTS:EAPIF) Short Interest Update Euroapi S.A. (OTCMKTS:EAPIF - Get Free Report) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 46,171 shares, a growth of…
businesswire.com Abolis Biotechnologies and EUROAPI Enter Into Partnership to Accelerate Pharmaceutical Innovation and Restore European Sovereignty ÉVRY-COURCOURONNES, France--(BUSINESS WIRE)--Abolis Biotechnologies, a company specializing in industrial solutions using microorganisms, today announced that it has entered into a strategic…
globenewswire.com With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of health sovereignty The project launch event, held at the Vertolaye site, brought together State officials, elected representatives, and several project partners to accelerate pharmaceutical innovation in Europe
globenewswire.com Science Based Targets initiative (SBTi) validates EUROAPI's near-term climate targets September 18, 2025 - EUROAPI's near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi1), confirming the company's alignment with the Paris…
seekingalpha.com Euroapi: Public Financing, Reorganization, And Very Cheap Euroapi is reorganizing under the FOCUS-27 plan, with significant restructuring costs but expected efficiency gains and free cash flow growth from 2026 onward. Recent European Commission funding and…
globenewswire.com EUROAPI sells Haverhill site to Particle Dynamics as part of its FOCUS-27 transformation plan Paris – June 30, 2025 – EUROAPI today announced the signing of a share purchase agreement (SPA) for the sale of 100% of EUROAPI UK Ltd, the subsidiary operating its Haverhill manufacturing site, with…
globenewswire.com Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce…
globenewswire.com EUROAPI moves into a new chapter with new Governance and Leadership Paris – December 9, 2024 – With FOCUS-27 strategic plan foundations established and its financing secured, EUROAPI moves into a new chapter. The company's Board of Directors has accepted today the…
globenewswire.com Olivier Falut appointed EUROAPI's Chief Financial Officer Paris – October 16, 2024 – Olivier Falut has been appointed EUROAPI's Chief Financial Officer, effective October 17, 2024, and will be a member of the Executive Committee. He is taking over from…
globenewswire.com EUROAPI closes the financing of its FOCUS-27 plan Paris - 15 October 2024 - EUROAPI today announces the closing of the refinanced Credit Revolving Facility (RCF) and the Perpetual Deeply Subordinated Hybrid Bond subscribed by Sanofi, thus completing…
globenewswire.com EUROAPI completes the financing of its FOCUS-27 plan and moves forward with its execution “The completion of the financing is an instrumental step in the execution of EUROAPI's strategic roadmap” said Ludwig de Mot, Chief Executive Officer. “ Combined with further developments in our…
businesswire.com Aizon Launches New AI-powered eBR Light Solution to Enhance Manufacturing Productivity in Collaboration with Euroapi SAN FRANCISCO--(BUSINESS WIRE)-- #gxp--Aizon, an Artificial Intelligence (AI) SaaS provider dedicated to transforming pharmaceutical manufacturing operations, is launching a new product called Aizon…
globenewswire.com EUROAPI - Availability of 2024 Half-Year Financial Report Paris, 05 August, 2024 – EUROAPI posted today its 2024 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2024. This document is available for consultation and…
globenewswire.com EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth1 Press Release Agreement with Sanofi on a 200 M€ investment through a Perpetual Subordinated Hybrid Bond, upon the completion of the ongoing discussions to amend and extend the current Revolving…
globenewswire.com EUROAPI and Priothera enter into CDMO collaboration to advance oncology project Paris – June 18, 2024 – EUROAPI announces today the implementation of a 5-year development and manufacturing agreement with Priothera, a biotechnology company specializing in molecules for the…